- Home
- GSK vs NTES Comparison
GSK vs NTES Comparison
Compare GSK & NTES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSK
- NTES
- Stock Information
- Founded
- GSK 1715
- NTES 1997
- Country
- GSK United Kingdom
- NTES China
- Employees
- GSK N/A
- NTES N/A
- Industry
- GSK Biotechnology: Pharmaceutical Preparations
- NTES Computer Software: Prepackaged Software
- Sector
- GSK Health Care
- NTES Technology
- Exchange
- GSK Nasdaq
- NTES Nasdaq
- Market Cap
- GSK 71.7B
- NTES 64.0B
- IPO Year
- GSK N/A
- NTES 2000
- Fundamental
- Price
- GSK $35.93
- NTES $98.73
- Analyst Decision
- GSK Hold
- NTES Strong Buy
- Analyst Count
- GSK 4
- NTES 7
- Target Price
- GSK $47.00
- NTES $114.57
- AVG Volume (30 Days)
- GSK 6.0M
- NTES 1.7M
- Earning Date
- GSK 04-30-2025
- NTES 05-22-2025
- Dividend Yield
- GSK 4.32%
- NTES 2.61%
- EPS Growth
- GSK N/A
- NTES 1.55
- EPS
- GSK 0.78
- NTES 1.26
- Revenue
- GSK $39,280,393,592.00
- NTES $14,425,783,434.00
- Revenue This Year
- GSK $7.60
- NTES $10.62
- Revenue Next Year
- GSK $5.24
- NTES $6.54
- P/E Ratio
- GSK $22.27
- NTES $15.88
- Revenue Growth
- GSK 3.46
- NTES 1.77
- 52 Week Low
- GSK $31.72
- NTES $75.85
- 52 Week High
- GSK $45.93
- NTES $110.15
- Technical
- Relative Strength Index (RSI)
- GSK 45.54
- NTES 48.83
- Support Level
- GSK $32.38
- NTES $96.68
- Resistance Level
- GSK $36.16
- NTES $100.81
- Average True Range (ATR)
- GSK 1.16
- NTES 3.39
- MACD
- GSK -0.13
- NTES -0.02
- Stochastic Oscillator
- GSK 52.28
- NTES 56.21
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
About NTES NetEase Inc.
Founded in the late 1990s as an internet portal, NetEase has transformed into a leading force in the second-largest online game company gaming in China. While its initial success was built upon the massively multiplayer online role-playing game Fantasy Westward Journey, NetEase has expanded its portfolio with captivating franchises that resonate with both domestic and international players. Over the past decade, the company has created titles such as Justice, Identity V, Naraka: Bladepoint, and Eggy Party, all of which maintain significant player bases today. Beyond in-house development, the company also collaborates with likes of Microsoft and Marvel to create and publish games based on renowned IPs, including World of Warcraft, Diablo Immortal, and Marvel Rivals.